Premium
Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia
Author(s) -
Raspadori Donatella,
Pacelli Paola,
Sicuranza Anna,
Abruzzese Elisabetta,
Iurlo Alessandra,
Cattaneo Daniele,
Gozzini Antonella,
Galimberti Sara,
Baratè Claudia,
Pregno Patrizia,
Nicolosi Maura,
Sorà Federica,
Annunziata Mario,
Luciano Luigiana,
Caocci Giovanni,
Moretti Sabrina,
Sgherza Nicola,
Fozza Claudio,
Russo Sabina,
Usala Emilio,
Liberati Marina A.,
Ciofini Sara,
Trawinska Monika M.,
Gozzetti Alessandro,
Bocchia Monica
Publication year - 2019
Publication title -
cytometry part b: clinical cytometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.646
H-Index - 61
eISSN - 1552-4957
pISSN - 1552-4949
DOI - 10.1002/cyto.b.21764
Subject(s) - flow cytometry , cd34 , myeloid leukemia , cd38 , haematopoiesis , population , stem cell , medicine , myeloid , leukemia , cytometry , immunology , bone marrow , pathology , microbiology and biotechnology , biology , genetics , environmental health
Background Recent investigations in chronic myeloid leukemia (CML) have focused on the identification and characterization of leukemic stem cells (LSCs). These cells reside within the CD34 + /CD38 ─ /Lin ─ fraction and score positive for CD26 (dipeptidylpeptidase IV) a marker, expressed in both bone marrow (BM) and peripheral blood (PB) samples, that discriminates CML cells from normal hematopoietic stem cells (HSCs) or from LSCs of other myeloid neoplasms. CD26 evaluation could be a useful tool to improve the identification of CML LCSs by using flow‐cytometry assay. Methods CD26 + LSCs have been isolated from EDTA PB and BM samples of patients with leucocytosis suspected for CML. Analysis of LSCs CML has been performed by using custom‐made lyophilized pre‐titrated antibody mixture test and control tube and a CD45 + /CD34 + /CD38 − /CD26 + panel as a strict flow cytometric gating strategy. Results The expression of CD26 on CD34 + /CD38 − population was detectable in 211/211 PB and 84/84 BM samples of subsequently confirmed BCR‐ABL + CP‐CML patients. None of the 32 samples suspicious for CML but scoring negative for circulating CD26 + LSCs were diagnosed as CML after conventional cytogenetic and molecular testing. To validate our results, we checked for PB CD26 + LSCs in patients affected by other hematological disorders and they all scored negative for CD26 expression. Conclusions We propose flow cytometry evaluation of CD26 expression on PB CD34 + /CD38 − population as a new rapid, reproducible, and powerful diagnostic tool for the diagnosis of CML. © 2019 The Authors. Cytometry Part B: Clinical Cytometry published by Wiley Periodicals, Inc. on behalf of International Clinical Cytometry Society.